Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ADCs - excess toxicities & unfavorable risk-benefit profiles

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Apr 24, 2023 9:14am

119 Views

Post# 35410099

RE:RE:RE:RE:RE:ADCs - excess toxicities & unfavorable risk-benefit profiles

Indeed Lesalpes. I think a few of us use Bay Bridge Bio & their biotech valuation material. They attribute a $1.248b usd valuation for a ph3 ready/approved biotech. They also mention the average cost of getting through a ph3 to market is about $405m. Interesting information. If we had 2 AA/ph3 ready trials we, according to Bay Bridge, should have a $35-$40 SP.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China